MASH significantly contributes to increased deaths and DALYs in the Americas, necessitating targeted public health policies. Despite declining hepatitis B-related liver disease, mortality from alcohol ...
In patients with severe metabolic dysfunction-associated steatohepatitis (MASH), the investigational drug efruxifermin significantly improved fibrosis without worsening MASH at 96 weeks versus placebo ...
"Our findings highlight the need for a shift in focus to younger generations. We can prevent liver cancer by tackling metabolic health issues early." — Pojsakorn Danpanichkul, MD, Texas Tech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback